Beyond Air, Inc. (XAIR): Price and Financial Metrics

Beyond Air, Inc. (XAIR): $5.34

0.04 (+0.75%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add XAIR to Watchlist
Sign Up

XAIR Price/Volume Stats

Current price $5.34 52-week high $11.76
Prev. close $5.30 52-week low $4.90
Day low $5.20 Volume 296,700
Day high $5.39 Avg. volume 317,143
50-day MA $5.91 Dividend yield N/A
200-day MA $6.71 Market Cap 160.69M

XAIR Stock Price Chart Interactive Chart >


Beyond Air, Inc. (XAIR) Company Bio


Beyond Air, Inc. operates as a medical device and biopharmaceutical company. The Company focuses on the discovery and development of a nitric oxide formulation and delivery systems to treat various respiratory diseases. Beyond Air serves patients and customers in the United States and Israel.


XAIR Latest News Stream


Event/Time News Detail
Loading, please wait...

XAIR Latest Social Stream


Loading social stream, please wait...

View Full XAIR Social Stream

Latest XAIR News From Around the Web

Below are the latest news stories about BEYOND AIR INC that investors may wish to consider to help them evaluate XAIR as an investment opportunity.

Beyond Air® Schedules Fiscal Year End 2023 Financial Results Conference Call and Webcast

Call scheduled for Thursday, June 22nd at 4:30 pm Eastern TimeGARDEN CITY, N.Y., May 16, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid t

Yahoo | May 16, 2023

Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the American Association for Cancer Research (AACR) 2023 Annual Meeting

Single and repeat dosing of UNO improves outcomes compared to checkpoint inhibitor monotherapy in the aggressive 4T1 breast cancer model mPD-L1 upregulation following UNO treatment helps to elucidate the mechanism for the previously reported sensitization of tumors to immune checkpoint blockade Phase 1 first-in-human study ongoing and expanded to multiple centers GARDEN CITY, N.Y. and HAMILTON, Bermuda, April 19, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NAS

Yahoo | April 19, 2023

Beyond Air® Appoints Jeff Myers, M.D. Ph.D. as Chief Medical Officer

Dr. Myers brings extensive executive experience leading the development of clinical programs through US and global regulatory approvalGARDEN CITY, N.Y., March 23, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through i

Yahoo | March 23, 2023

Beyond Cancer™ to Present Two Posters for Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2023 AACR Annual Meeting

Proffered abstracts accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting were released publicly today at 4:30 PM EDTGARDEN CITY, N.Y. and HAMILTON, Bermuda, March 14, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced that Beyond Cancer, Ltd. will present two posters at the upcoming American

Yahoo | March 14, 2023

Beyond Air® Announces Participation at Two Upcoming Investor Conferences in March 2023

GARDEN CITY, N.Y., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that St

Yahoo | February 22, 2023

Read More 'XAIR' Stories Here

XAIR Price Returns

1-mo -7.77%
3-mo -12.17%
6-mo -8.56%
1-year -9.18%
3-year -21.35%
5-year 75.02%
YTD -17.72%
2022 -31.25%
2021 79.13%
2020 0.76%
2019 12.47%
2018 -6.81%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!